Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Waters, Valerie ^a   Ratjen, Felix ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL COUNT; BIOFILM; CANADA; CLINICAL OUTCOME; COMPARATIVE STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; EVIDENCE BASED MEDICINE; HUMAN; LUNG FUNCTION; LUNG INFECTION; META ANALYSIS; MULTICENTER STUDY (TOPIC); PATIENT SAFETY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM; STANDARD; SYSTEMATIC REVIEW; UNITED STATES; ADOLESCENT; ADULT; COMPLICATION; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BIOFILMS; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; SPUTUM;

EID: 84942794573     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009528.pub3     Document Type: Review

References (50)

1. Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatric Pulmonology 2011;46(2):184-92. [CFGD Register: PI245]
2. Ratjen F, Stanojevic S, Sonneveld N, Grasemann H, Yau Y, Tullis E, et al. Predictors of response to antibiotic treatment of pulmonary exacerbations in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:355, Abstract no: 384. [CENTRAL: 1012525; CFGD Register: PI244c ; CRS: 5500131000000179]
3. Waters V, Ratjen F, Tullis E, Corey M, Matukas L, Leahy R, et al. Randomized double blind controlled trials of the use of a biofilm antimicrobial susceptibility assay to guide antibiotic therapy in chronic pseudomonas aeruginosa infected cystic fibrosis patients [abstract]. Pediatric Pulmonology 2010;45(Suppl 33):339, Abstract no: 311. [CFGD Register: PI244a]
4. Waters VJ, Ratjen F, Tullis E, Wilcox PG, Freitag A, Chilvers M, et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in pulmonary exacerbations in cystic fibrosis patients with chronic pseudomonas aeruginosa infection [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:319, Abstract no: 287. [CFGD Register: PI244b ; CRS: 5500131000000178]
5. Yau YCW, Ratjen F, Tullis E, Wilcox P, Freitag A, Chilvers M, et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis 2014 November 19 [Epub ahead of print]. [CENTRAL: 1015278; CFGD Register: PI244d ; CRS: 5500131000000261]
6. Aaron S. Clinical evidence for combination antibiotic susceptibility testing (synergy testing) [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):157. [CFGD Register: PI198c]
7. Aaron S, Vandemheen K, Ferris W, Tullis E, Haase D, Berthiaume Y, et al. Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial [abstract]. Pediatric Pulmonology 2005;40(Suppl 28):304. [CFGD Register: PI198a]
8. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366(9484):463-71. [CFGD Register: PI198b]
9. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson R, McKevitt M, Montgomery B. Antibiotic susceptibility in Pseudomonas Aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 2009;44(Suppl 32):309, Abstract no: 278. [CFGD Register: PI220a]
10. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson R, McKevitt M, Montgomery B. Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens [abstract]. Pediatric Pulmonology 2009;44(Suppl 32):335, Abstract no: 353. [CFGD Register: PI220d]
11. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Montgomery AB. Effect of multiple courses of Aztreonam Lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006 [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S28, Abstract no: 107. [CFGD Register: PI220c]
12. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Quittner AL, Montgomery AB. Adherence over multiple courses of Aztreonam for inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S28, Abstract no: 109. [CFGD Register: PI220b]
13. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology 2010;45(11):1121-34. [CFGD Register: PI220e]
14. Quittner AL, Henig NR, Lewis S, Derchak PA, McCoy KS, Oermann CM, et al. Effects of chronic intermittent aztreonam for inhalation solution (AZLI) on health-related quality of life (HRQOL) in persons with cystic fibrosis (CF) and P. aeruginosa [abstract]. Pediatric Pulmonology 2011;46 Suppl 34:299, Abstract no: 240. [CENTRAL: 867260; CFGD Register: PI220f // PI213j; CRS: 5500100000011261]
15. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatric Pulmonology 2009;44(6):547-58.
16. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases 2001;183(3):444-52.
17. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. Journal of Clinical Microbiology 1999;37(6):1771-6.
18. Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA. Antibiotic Management of Lung Infections in Cystic Fibrosis: Part I. The Microbiome, MRSA, Gram-Negative Bacteria, and Multiple Infections. Ann Am Thorac Soc 2014 Sep;11(7):1120-9.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Vol. Twenty-second informational supplement M100-S22, Wayne, PA: Clinical & Laboratory Standards Institute, 2012. [ISBN-10: 1562388983]
20. Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomized trials. Statistical Methods in Medical Research 2001;10(5):325-38.
21. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416(6882):740-3.
22. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
23. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy 2005;55(6):921-7.
24. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatric Pulmonology 1996;21(3):153-8.
25. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine 1994;331(10):637-42.
26. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54.
27. Gibson RL, Burns JL. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51.
28. Gilligan PH. Is there value in susceptibility testing of Pseudomonas aeruginosa causing chronic infection in patients with cystic fibrosis?. Expert Review of Anti-infective Therapy 2006;4(5):711-5.
29. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatric Pulmonology. 1992;12(3):158-61.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
31. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
32. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clinical Infectious Diseases 2009;49(11):1749-55.
34. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatric Pulmonology 2001;32(4):277-87.
35. MacGowan AP, BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. Journal of Antimicrobial Chemotherapy 2008;62(Suppl 2):ii105-14.
36. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Clinical Microbiology 2004;42(5):1915-22.
37. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. Journal of Antimicrobial Chemotherapy 2005;56(5):879-86.
38. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Current Opinion in Pediatrics 2007;19(1):83-8.
39. Pamukcu A, Bush A, Buchdahl R. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatric Pulmonology 1995;19(1):10-5.
40. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
41. Prince AS. Biofilms, antimicrobial resistance, and airway infection. New England Journal of Medicine 2002;347(14):1110-1.
42. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
43. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. New England Journal of Medicine 1996;335(3):179-88.
44. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407(6805):762-4.
45. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123(5):1495-502.
46. Sterne JAC, Egger M, Moher D on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
47. Schobert M, Tielen P. Contribution of oxygen-limiting conditions to persistent infection of Pseudomonas aeruginosa. Future Microbiology 2010;5(4):603-21.
48. Wagner T, Soong G, Sokol S, Saiman L, Prince A. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 2005;128(2):912-9.
49. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006961.pub2]
50. Waters V, Ratjen F. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD009528.pub2]